Results from a recent study have indicated that semaglutide may serve as an effective therapeutic option for patients who have immunoglobulin A (IgA) nephropathy and overweight or obesity without diabetes who are undergoing conventional treatment regimens.
Glucagon-like peptide-1 receptor agonist (GLP-1RA) can significantly decrease the risk of cardiovascular events in patients with or without diabetes. Prior research has indicated that semaglutide, a GLP-1 analogue, effectively reduces body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes.2
Additionally, semaglutide has displayed renoprotective effects in patients with diabetes and chronic kidney disease. Investigators believe potential mechanisms for these effects may include oxidative stress reduction, inflammation, and…